Treatment of relapsed and refractory acute myelogenous leukemia

E H Estey


Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than investigational regimens, these rates have not translated into improved survival in patients with initial remission durations of <1 year. Accordingly, there is no need to give standard regimens to these patients who rather should receive investigational therapy once relapse is discovered. In contrast, in patients with initial remission durations of 1-2 years, standard regimens do increase survival compared to investigational regimens. A somewhat artificial distinction has been placed between phase I and phase II studies. The agents to be studied in phase II trials are many, but the patients are limited, so we need to be more innovative in our trial designs. One such proposal, utilizing a Bayesian selection design which calls for randomizing a small number of patients among several investigational treatments, will be discussed.


Jun 15, 1995·Statistics in Medicine·S N GoodmanS Piantadosi
Dec 1, 1961·Journal of Chronic Diseases·E J FREIREICHE FREI

❮ Previous
Next ❯


Aug 7, 2002·Current Oncology Reports·Edward A Stadtmauer
Jan 30, 2008·International Journal of Hematology·Akira HorikoshiShigemasa Sawada
Apr 1, 1989·European Journal of Cancer & Clinical Oncology·F Bessho
Dec 7, 2013·Best Practice & Research. Clinical Haematology·Farhad Ravandi
Dec 20, 2003·Blood Reviews·Mark R Litzow
Jan 10, 2012·Current Opinion in Hematology·Yishai Ofran, Jacob M Rowe
Feb 7, 2013·Current Opinion in Hematology·Timothy Kubal, Jeffrey E Lancet
Jun 12, 2012·PPAR Research·Yoko TabeAkimichi Ohsaka
Jun 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca B KlisovicGuido Marcucci
May 26, 2009·Journal of Hematology & Oncology·Karen SeiterNasir Ahmed
Jul 5, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·A E FrankelJ G Jurcic
Dec 29, 2012·Leukemia & Lymphoma·Ellen K RitchieGail J Roboz
Sep 14, 2012·Expert Opinion on Pharmacotherapy·Katarzyna Jamieson, Olatoyosi Odenike
Mar 1, 2006·Expert Review of Anticancer Therapy·Norbert Vey, Frank Giles
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Norbert Vey, Frank Giles
Feb 10, 2016·Frontiers in Pharmacology·Neha S BhiseJatinder K Lamba
Jul 4, 2012·Prostaglandins, Leukotrienes, and Essential Fatty Acids·Shahrzad Soleymani FardAli M Ardekani
Oct 8, 2011·Leukemia Research·Oliver J Stoetzer
Sep 25, 2014·American Journal of Hematology·Naveen PemmarajuFarhad Ravandi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.